Thank you, Mr. Speaker. I appreciate the Member’s consideration or suggestion that we don’t care or we’re not taking this particularly seriously. I would like to suggest that, in fact, we do take this very seriously and are monitoring where appropriate. I can’t say why there isn’t more prevalence or more indication. We do monitor; we do track. I would also suggest that the Member take a closer look at the report, because we do see increased rates in some of our communities. It just doesn’t happen to be in all of our communities. We are tracking, Mr. Speaker.